The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease

Aside from their role in hemostasis, coagulant and fibrinolytic proteases are important mediators of inflammation in diseases such as asthma, atherosclerosis, rheumatoid arthritis, and cancer. The blood circulating zymogens of these proteases enter damaged tissue as a consequence of vascular leak or...

Full description

Bibliographic Details
Main Author: Michael Schuliga
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2015/437695
id doaj-a99fedd962a34935b3dd2b0704f16c0d
record_format Article
spelling doaj-a99fedd962a34935b3dd2b0704f16c0d2020-11-24T22:30:28ZengHindawi LimitedMediators of Inflammation0962-93511466-18612015-01-01201510.1155/2015/437695437695The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in DiseaseMichael Schuliga0Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 3010, AustraliaAside from their role in hemostasis, coagulant and fibrinolytic proteases are important mediators of inflammation in diseases such as asthma, atherosclerosis, rheumatoid arthritis, and cancer. The blood circulating zymogens of these proteases enter damaged tissue as a consequence of vascular leak or rupture to become activated and contribute to extravascular coagulation or fibrinolysis. The coagulants, factor Xa (FXa), factor VIIa (FVIIa), tissue factor, and thrombin, also evoke cell-mediated actions on structural cells (e.g., fibroblasts and smooth muscle cells) or inflammatory cells (e.g., macrophages) via the proteolytic activation of protease-activated receptors (PARs). Plasmin, the principle enzymatic mediator of fibrinolysis, also forms toll-like receptor-4 (TLR-4) activating fibrin degradation products (FDPs) and can release latent-matrix bound growth factors such as transforming growth factor-β (TGF-β). Furthermore, the proteases that convert plasminogen into plasmin (e.g., urokinase plasminogen activator) evoke plasmin-independent proinflammatory actions involving coreceptor activation. Selectively targeting the receptor-mediated actions of hemostatic proteases is a strategy that may be used to treat inflammatory disease without the bleeding complications of conventional anticoagulant therapies. The mechanisms by which proteases of the coagulant and fibrinolytic systems contribute to extravascular inflammation in disease will be considered in this review.http://dx.doi.org/10.1155/2015/437695
collection DOAJ
language English
format Article
sources DOAJ
author Michael Schuliga
spellingShingle Michael Schuliga
The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease
Mediators of Inflammation
author_facet Michael Schuliga
author_sort Michael Schuliga
title The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease
title_short The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease
title_full The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease
title_fullStr The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease
title_full_unstemmed The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease
title_sort inflammatory actions of coagulant and fibrinolytic proteases in disease
publisher Hindawi Limited
series Mediators of Inflammation
issn 0962-9351
1466-1861
publishDate 2015-01-01
description Aside from their role in hemostasis, coagulant and fibrinolytic proteases are important mediators of inflammation in diseases such as asthma, atherosclerosis, rheumatoid arthritis, and cancer. The blood circulating zymogens of these proteases enter damaged tissue as a consequence of vascular leak or rupture to become activated and contribute to extravascular coagulation or fibrinolysis. The coagulants, factor Xa (FXa), factor VIIa (FVIIa), tissue factor, and thrombin, also evoke cell-mediated actions on structural cells (e.g., fibroblasts and smooth muscle cells) or inflammatory cells (e.g., macrophages) via the proteolytic activation of protease-activated receptors (PARs). Plasmin, the principle enzymatic mediator of fibrinolysis, also forms toll-like receptor-4 (TLR-4) activating fibrin degradation products (FDPs) and can release latent-matrix bound growth factors such as transforming growth factor-β (TGF-β). Furthermore, the proteases that convert plasminogen into plasmin (e.g., urokinase plasminogen activator) evoke plasmin-independent proinflammatory actions involving coreceptor activation. Selectively targeting the receptor-mediated actions of hemostatic proteases is a strategy that may be used to treat inflammatory disease without the bleeding complications of conventional anticoagulant therapies. The mechanisms by which proteases of the coagulant and fibrinolytic systems contribute to extravascular inflammation in disease will be considered in this review.
url http://dx.doi.org/10.1155/2015/437695
work_keys_str_mv AT michaelschuliga theinflammatoryactionsofcoagulantandfibrinolyticproteasesindisease
AT michaelschuliga inflammatoryactionsofcoagulantandfibrinolyticproteasesindisease
_version_ 1725740854826500096